Should I Buy TRVI? TRVI 2026 Analysis

Should You Buy Trevi Therapeutics Inc (TRVI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

10.690

1 Day change

1.71%

52 Week Range

14.390

Analysis Updated At

2026/01/26

Trevi Therapeutics Inc (TRVI) is not a strong buy at this moment for a beginner, long-term investor. While the company has promising developments in its pipeline and positive analyst sentiment, the technical indicators are weak, financial performance is declining, and there are no significant trading trends or proprietary trading signals to support an immediate buy decision. The stock is better suited for monitoring rather than immediate action.

Technical Analysis

The MACD is negatively expanding (-0.129), RSI is neutral at 29.692, and moving averages are converging, indicating no clear bullish trend. The stock is trading near support levels (S1: 10.162, S2: 9.736), but there is no strong upward momentum.

Options Data

Bearish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Positive Phase 2b CORAL trial results showing significant reductions in cough frequency.
Analysts have raised price targets and maintain strong ratings, citing regulatory clarity and potential market opportunities.
Cash runway anticipated into 2028, providing financial stability for ongoing developments.

Neutral/Negative Catalysts

Weak technical indicators with no clear upward momentum.
Financial performance in Q3 2025 shows declining net income (-10.87% YoY) and EPS (-38.46% YoY).
No significant trading trends from hedge funds or insiders, and no recent congress trading data.

Financial Performance

In Q3 2025, revenue remained at $0 with no growth YoY. Net income dropped by -10.87% YoY to -$11.8M, and EPS fell by -38.46% YoY to -$0.08. Gross margin remains at 0%. The financials indicate the company is still in its development phase with no revenue generation.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are optimistic about TRVI, with multiple firms raising price targets (e.g., Stifel to $18, Oppenheimer to $24, Morgan Stanley to $19, Clear Street to $21). They highlight the company's progress in regulatory clarity and its pipeline development for chronic cough treatments.

9 Analyst Rating

Wall Street analysts forecast TRVI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRVI is 21.22 USD with a low forecast of 16 USD and a high forecast of 25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

0 Hold

0 Sell

Strong Buy

Current: 10.510

Low

Averages

21.22

High

Current: 10.510

Low

Averages

21.22

High

Stifel

Buy

maintain

$15 -> $18

AI Analysis

2025-12-19

Reason

Stifel

Price Target

$15 -> $18

AI Analysis

2025-12-19

maintain

Buy

Reason

Stifel raised the firm's price target on Trevi Therapeutics to $18 from $15 and keeps a Buy rating on the shares as part of a 2026 outlook note for the analyst's Biopharma coverage.

Oppenheimer

Leland Gershell

Outperform

maintain

$23 -> $24

2025-11-14

Reason

Oppenheimer

Leland Gershell

Price Target

$23 -> $24

2025-11-14

maintain

Outperform

Reason

Oppenheimer analyst Leland Gershell raised the firm's price target on Trevi Therapeutics to $24 from $23 and keeps an Outperform rating on the shares. The firm notes the company provided updates across Haduvio's development in chronic cough settings, with the plan to begin the Phase 3 IPF chronic cough program - as well as advance into Phase 2b for refractory chronic cough - in the first half of 2026. Next year should also see the start of a Phase 2 in non-IPF idiopathic lung disease chronic cough, an opportunity that may be as large as IPF CC itself. Cash runway anticipated into 2028, and Oppenheimer sees meaningful upside as Haduvio's momentum toward commercial builds for a growing group of poorly served chronic cough indications.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TRVI

Unlock Now

TRVI Should I Buy

TRVI Should I Buy

Should You Buy Trevi Therapeutics Inc (TRVI) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch